ArticleCureus2026
Gestational Trophoblastic Disease in a Resource-Limited Setting: A Prospective Study of Molar Pregnancy at a Teaching Hospital in Northeast India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Molar pregnancy is a premalignant form of gestational trophoblastic disease with a higher incidence reported in Asian populations. Data from Northeast India, where geographic and healthcare disparities may influence disease patterns and outcomes, remain limited. Methods This prospective observational study was conducted over 15 months at a tertiary care teaching hospital in Northeast India. Women aged 15-49 years with ultrasonography- and histopathology-confirmed molar pregnancy were included. Clinical and treatment data were recorded, and patients were followed with serial serum β-human chorionic gonadotropin (β-hCG) until normalization. Predictors of chemotherapy requirement were analyzed using logistic regression and ROC curve analysis. Results The mean age was 27.8±5.5 years. Common presenting features included amenorrhoea and vaginal bleeding. Complete mole was the predominant subtype (75.9%). Suction evacuation was performed in 83.3% of patients as primary treatment, while 22.2% needed chemotherapy. On multivariate analysis, β-hCG ≥100,000 mIU/mL (aOR 4.9, p=0.003) and uterine size greater than gestational age (aOR 2.8, p=0.048) were independent predictors of chemotherapy. Receiver operating characteristic (ROC) analysis showed good predictive performance (AUC 0.78). Ultrasonography showed moderate agreement with histopathology (kappa=0.62). Discussion The age and socioeconomic patterns differed from traditional risk profiles, suggesting regional and genetic influences on disease distribution. Management outcomes are favourable, supported by improved imaging facilities, effective treatment, and meticulous surveillance. β-hCG demonstrates good discriminatory ability and may aid early risk stratification. Larger multicentric studies are needed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.